YeoYHHoHJYangHI, et al.Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology2019; 156: 635–646.e9.
2.
LiawYFChuCM. Hepatitis B virus infection. Lancet2009; 373: 582–592.
3.
SharmaSKMohanA. Miliary tuberculosis: a new look at an old foe. J Clin Tuberc Other Mycobact Dis2019; 17: 100122.
4.
ScribaTJCoussensAKFletcherHA. Human immunology of tuberculosis. Microbiol Spectr2017; 5. DOI: 10.1128/microbiolspec.TBTB2-0016-2016.
5.
BertolettiAKennedyPT. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol2015; 12: 258–263.
6.
EleftheriadisTAntoniadiGLiakopoulosV, et al.Disturbances of acquired immunity in hemodialysis patients. Semin Dial2007; 20: 440–451.
7.
LiawYFChenYCSheenIS, et al.Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology2004; 126: 1024–1029.
8.
SagnelliECoppolaNPisaturoM, et al.Functional cure of chronic hepatitis B by acute hepatitis A superinfection: a multicenter study. Clin Infect Dis2006; 42: 738–742.
9.
WedemeyerHMannsMP. Epidemiology, pathogenesis and management of Hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol2010; 7: 31–40.
10.
AudsleyJAvihingsanonALiX, et al.Kinetics and predictors of hepatitis B surface antigen (HBsAg) loss after commencing HBV-active antiretroviral therapy in HIV/HBV coinfection. Clin Infect Dis2025; 31: ciaf281.
11.
ChenLWangJXuH, et al.Immune reconstitution inflammatory syndrome associated with HBV in HIV coinfected patients: clinical features and outcomes. Infect Dis Int2023; 12: 145–153.
12.
ZiglamHMDanielsIFinchRG. Immunomodulating activity of rifampicin. J Chemother2004; 16: 357–361.
